Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Sunday. The brokerage issued a hold rating on the medical research company’s stock.

Several other equities research analysts have also commented on the stock. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research note on Friday. HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Cytosorbents has an average rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Stock Up 1.8 %

Cytosorbents stock opened at $0.94 on Friday. The firm has a market capitalization of $51.21 million, a P/E ratio of -2.60 and a beta of 0.58. The company has a 50-day simple moving average of $0.92 and a 200-day simple moving average of $1.02. Cytosorbents has a one year low of $0.70 and a one year high of $1.59. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Institutional Trading of Cytosorbents

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after acquiring an additional 192,747 shares during the period. Atomi Financial Group Inc. bought a new position in Cytosorbents during the 3rd quarter valued at $51,000. Finally, Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.